trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Medicines can be used to shrink the prostate and improve urine flow in men.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
3 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that medicines can be used to shrink the prostate and improve urine flow in men?

Yes. Medicines such as 5-alpha-reductase inhibitors and other hormone-targeted therapies are well-established treatments that effectively reduce prostate size and improve urinary flow in men with lower urinary tract symptoms.

Verdict: SUPPORTED · 3 sources for, 0 against · Last checked

The analysis

The retrieved papers uniformly support the claim that medical therapies (such as 5-alpha-reductase inhibitors and androgen deprivation treatments) shrink the prostate and alleviate lower urinary tract symptoms. Multiple clinical studies and reviews corroborate this physiological effect.

Evidence for · 3
Impact of Androgen Deprivation Therapy on Volume Reduction and Lower Urinary Tract Symptoms in Patients with Prostate Cancer
2016
This study demonstrates that androgen deprivation therapy reduces prostate volume and improves lower urinary tract symptoms in patients.
Get citation
WASHINO, S., HIRAI, M., SAITO, K., KOBAYASHI, Y., ARAI, Y., & MIYAGAWA, T. (2016). Impact of Androgen Deprivation Therapy on Volume Reduction and Lower Urinary Tract Symptoms in Patients with Prostate Cancer. doi.org. https://doi.org/10.1111/luts.12142

See more details
More for · 2
5 Alpha Reductase Inhibitors (5ARIs) Monotherapy and Combinations: Current Role in Benign Prostatic Hyperplasia (BPH) Management
2026
This review highlights that 5-alpha-reductase inhibitors effectively reduce prostate volume and manage lower urinary tract symptoms in benign prostatic hyperplasia.
Get citation
Roidos, C., Sountoulides, P., Papathanasiou, K., Symeonidis, A., & Mykoniatis, I. (2026). 5 Alpha Reductase Inhibitors (5ARIs) Monotherapy and Combinations: Current Role in Benign Prostatic Hyperplasia (BPH) Management. doi.org. https://doi.org/10.3390/medicina62050975

BENIGN PROSTATIC HYPERPLASIA: A CASE STUDY USING ALPHA BLOCKER AND 5-ALPHA REDUCTASE INHIBITORS COMBINATION THERAPY
2022
This case study reports that medical therapy using alpha blockers and 5-alpha reductase inhibitors successfully ameliorated lower urinary tract symptoms.
Get citation
John, I. O. (2022). BENIGN PROSTATIC HYPERPLASIA: A CASE STUDY USING ALPHA BLOCKER AND 5-ALPHA REDUCTASE INHIBITORS COMBINATION THERAPY. doi.org. https://doi.org/10.36099/mamr.210322

What does the evidence say?

The retrieved papers uniformly support the claim that medical therapies (such as 5-alpha-reductase inhibitors and androgen deprivation treatments) shrink the prostate and alleviate lower urinary tract symptoms. Multiple clinical studies and reviews corroborate this physiological effect.

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work